SEC Form 10-Q filed by Beam Therapeutics Inc.
$BEAM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/6/2024 | $27.00 → $39.00 | Market Perform → Outperform | Leerink Partners |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 7/23/2024 | $80.00 | Buy | H.C. Wainwright |
| 1/29/2024 | $38.00 → $40.00 | Neutral → Overweight | JP Morgan |
| 12/15/2023 | $35.00 | Buy → Neutral | BofA Securities |
| 12/8/2023 | $75.00 → $30.00 | Buy → Hold | Jefferies |
| 10/20/2023 | Overweight → Neutral | Cantor Fitzgerald | |
| 10/20/2023 | $75.00 → $20.00 | Outperform → Market Perform | Leerink Partners |
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Tuesday. Shares of Danaher Corporation (NYSE:DHR) rose sharply during Tuesday's session after the company reported better-than-expected second quarter earnings. Danaher's second quarter sales decreased 3% year-over-year to $5.743 billion, beating the consensus of $5.59 billion. Danaher reported second-quarter adjusted EPS of $1.72, beating the consensus of $1.57, according to data from Benzinga Pro. Danaher shares gained 7.4% to $269.35 on Tuesday. Here are some other big stocks recording gains in today’s session. Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) shares jumped 16% to $24.81 af
HC Wainwright & Co. analyst Patrick Trucchio initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Buy rating and announces Price Target of $80.
SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)
SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)
SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)
10-Q - Beam Therapeutics Inc. (0001745999) (Filer)
8-K - Beam Therapeutics Inc. (0001745999) (Filer)
8-K - Beam Therapeutics Inc. (0001745999) (Filer)
Leerink Partners upgraded Beam Therapeutics from Market Perform to Outperform and set a new price target of $39.00 from $27.00 previously
Scotiabank initiated coverage of Beam Therapeutics with a rating of Sector Outperform
H.C. Wainwright initiated coverage of Beam Therapeutics with a rating of Buy and set a new price target of $80.00
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 10:00 a.m. GMT in London. A live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation. About Beam TherapeuticsBeam Therapeutics (NASDAQ:BEAM) is a biotechnology company committed to establishing the leading, fully integrated p
Initial Results from BEACON Phase 1/2 Clinical Trial Demonstrate Potential for Differentiation of Base Editing and BEAM-101 Preclinical ESCAPE Data Establish Proof-of-concept for Non-genotoxic, Antibody-based Conditioning and Engraftment in Non-human Primates Clinical Data from Phase 1/2 BEAM-201 Trial Demonstrate Therapeutic Potential of First Quadruplex-edited Allogeneic CAR-T Cell Therapy Beam to Host Investor Event on Dec. 8, 2024, at 8 p.m. PT CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the acceptance of
Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting 35 Patients Enrolled and Eight Patients Dosed in BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease First Cohort Dosing Completed in Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency; Initial Clinical Data Expected in 2025 Ended Third Quarter 2024 with $925.8 Million in Cash, Cash Equivalents and Marketable Securities; Expected Operating Runway into 2027 Company to Host Conference Call Today, November 5, 2024, at 8:30 a.m. ET CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NA
4 - Beam Therapeutics Inc. (0001745999) (Issuer)
4 - Beam Therapeutics Inc. (0001745999) (Issuer)
4 - Beam Therapeutics Inc. (0001745999) (Issuer)
Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting 35 Patients Enrolled and Eight Patients Dosed in BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease First Cohort Dosing Completed in Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency; Initial Clinical Data Expected in 2025 Ended Third Quarter 2024 with $925.8 Million in Cash, Cash Equivalents and Marketable Securities; Expected Operating Runway into 2027 Company to Host Conference Call Today, November 5, 2024, at 8:30 a.m. ET CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NA
CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will host a conference call and webcast on Tuesday, November 5, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results and review the company's abstracts accepted for presentation at the upcoming 66th Annual Meeting of the American Society for Hematology (ASH). A live webcast of the presentation will be available here and under "Events & Presentations" in the Investors section of the company's website at www.beamtx.com. A replay of the webcast will be archived on the com
Recent Portfolio Prioritization Focuses Business on Key Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline Lilly Acquires Beam's Opt-In Rights to Verve Therapeutics' Base Editing Cardiovascular Programs for up to $600 Million in Combined Upfront Payment, Equity Investment and Potential Future Development-Stage Payments GMP Operations Initiated at Beam's North Carolina Manufacturing Facility Strong Balance Sheet Provides Anticipated Operating Runway into the Second Half of 2026 CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, to
CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Christi Shaw to the company's board of directors. "Christi is an inspiring leader who knows firsthand what it takes to transform cutting-edge science into practice-changing commercial treatment options, most recently building and scaling the industry's premier autologous cell therapy company as CEO of Kite," said John Evans, chief executive officer of Beam Therapeutics. "Her experience leading the transformation of novel science into approved medicines, coupled with her unwavering d
CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Gopi Shanker, Ph.D., has been appointed as chief scientific officer (CSO). Dr. Shanker is a scientific leader with more than 20 years of drug development experience as well as experience with novel genetic medicine modalities. Dr. Shanker will report to Giuseppe Ciaramella, Ph.D., president of Beam, who has broad oversight of Beam's research, manufacturing, regulatory, quality and pharmaceutical sciences organizations. "We are thrilled to welcome Gopi to the Beam team during this exciting time a
Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience WINSTON-SALEM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease ("CKD"), today announced the appointments of John M. Maraganore, Ph.D. and Jennifer Fox to its Board of Directors. "We are thrilled to welcome John and Jen to the ProKidney Board. They each have a wealth of experience t